Disease-free survival as a surrogate for overall survival in HR+/HER2 − early breast cancer: a correlation analysis

Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone receptor –positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) EBC.

Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Michael Untch, David P érol, Erica L. Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima Pathak, Peter A. Fasching Tags: Original Research Source Type: research